Elevated phosphatidylserine-specific phospholipase A1 level in hyperthyroidism

• Published in: Clinica chimica acta Vol. 503; pp. 99 - 106
• Main Authors: Nakawatari, Kazuki, Kurano, Makoto, Araki, Osamu, Nishikawa, Masako, Shimamoto, Satoshi, Igarashi, Koji, Aoki, Junken, Murakami, Masami, Yatomi, Yutaka
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.04.2020
• Subjects: Anti-thyroid drugs; Graves’ disease; Hyperthyroidism; Lysophosphatidylserine; Phosphatidylserine-specific phospholipase A1; Thyroid hormones; Phosphatidylserine-specific phospholipase A1; PS-PLA1; LysoPS; fT3; GPR34; ALP; Hyperthyroidism; fT4; ROC; TSH; P2Y10; Lysophosphatidylserine; Graves’ disease; SNPs; TRAb; Thyroid hormones; Anti-thyroid drugs
• ISSN: 0009-8981; 1873-3492; 1873-3492
• DOI: 10.1016/j.cca.2020.01.011

•The serum PS-PLA1 levels were higher in hyperthyroidism such as Graves’ disease.•The serum PS-PLA1 levels were strongly correlated with thyroid hormones.•The serum PS-PLA1 levels were lowered by treatment with anti-thyroid reagents.•The changes in PS-PLA1 were strongly correlated with those in thyroid hormones.•PS-PLA1 might be useful as a supplementary diagnostic test for thyroid function. Although a single nucleotide polymorphism in a specific receptor for lysophosphatidylserine, a lysophospholipid mediator involved in the immune system, is reportedly associated with Graves’ disease, the association between lysophosphatidylserine and thyroid disorders remains to be elucidated. Therefore, we aimed to investigate the association between the level of phosphatidylserine-specific phospholipase A1 (PS-PLA1), which produces lysophosphatidylserine, and thyroid disorders. We measured serum PS-PLA1 levels in the patients with various thyroid disorders (n = 120) and normal subjects (n = 58). We observed that the serum PS-PLA1 levels were higher in the subjects with Graves’ disease, subacute thyroiditis, or silent thyroiditis, while they were not modulated in the patients with hypothyroidism. The serum PS-PLA1 levels were strongly correlated with the levels of thyroid hormones, especially in the subjects with Graves’ disease. Moreover, we found that the serum PS-PLA1 levels were lowered by treatment with anti-thyroid reagents in subjects with Graves’ disease and that the changes in PS-PLA1 were strongly correlated with those in thyroid hormones. These results suggest that PS-PLA1 might be a novel target in the treatment of hyperthyroidism, especially Graves’ disease, and that its measurement might be useful as a supplementary diagnostic test for thyroid function.